Logo

BMS Signs an Exclusive Worldwide Agreement with Repare Therapeutics to Identify Multiple Precision Oncology Therapies

Share this

BMS Signs an Exclusive Worldwide Agreement with Repare Therapeutics to Identify Multiple Precision Oncology Therapies

Shots:

  • BMS to receive $65M up front- including $15M equity investment and is eligible to receive $3B as license fees- discovery- development- regulatory and commercial milestones- in addition to royalty payments on commercialization of each product commercialized by BMS
  • The companies will Repare’s SNIPRx platform to jointly identify multiple synthetic lethal precision oncology targets for drug candidates. BMS will get exclusive WW rights to develop and commercialize therapies for select validated synthetic lethal precision oncology targets emerges during the collaboration
  • Repare’s SNIPRx platform is a genome-wide CRISPR-based screening platform that utilizes isogenic cell lines to identify synthetic lethal gene pairs and the corresponding patients who may get benefit from therapies

Click here to read full press release/ article |

Ref: Business wire | Image: BMS 


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions